Peter Neumann in New England Journal of Medicine: Cost-Effectiveness 2.0 -- Poised for a Second Act?

PHE Scientific Advisor Peter Neumann, along with co-author Gillian Sanders, offers a new perspective on cost-effectiveness analysis, just published in the New England Journal of Medicine. Neumann and Sanders provide an overview of recent work, and argue that cost-effectiveness analysis should be an essential part of healthcare decision making.

To read the article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.